Biotechnology News and Research

RSS

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

Positive activity interventions effective in treatment of depressive disorders

Positive activity interventions (PAIs) offer a safe, low-cost, and self-administered approach to managing depression and may offer hope to individuals with depressive disorders who do not respond or have access to adequate medical therapy, according to a comprehensive review article in The Journal of Alternative and Complementary Medicine, a peer-reviewed journal published by Mary Ann Liebert, Inc.

4 Aug 2011

Scientists to develop fast, portable and inexpensive urine test for TB

Scientists are reporting an advance toward a fast, inexpensive urine test to detect and monitor the effectiveness of treatment for tuberculosis (TB), which is on a rampage in the developing world.

4 Aug 2011

ImmunoCellular receives new patent for ICT-69 to treat multiple myeloma, ovarian cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a patent in France and the United Kingdom relating to the treatment and detection of multiple myeloma and ovarian cancer.

4 Aug 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

SuperGen second quarter net income decreases to $903,000

SuperGen, Inc. today reported financial results for the second quarter ended June 30, 2011. The Company reported net income for the 2011 second quarter of $903,000, or $0.01 per basic and diluted share, compared with $961,000, or $0.02 per basic and diluted share, for the same prior year period.

3 Aug 2011

Zalicus second quarter revenue decreases to $1.8 million

Zalicus Inc. today reported financial results for the second quarter ended June 30, 2011.

3 Aug 2011

UTHealth student receives UNCF/Merck fellowship for multidrug-resistant CDI research

Charles Darkoh, a graduate student at The University of Texas Health Science Center at Houston (UTHealth), has been awarded a fellowship from the United Negro College Fund (UNCF) and Merck for his research into a major health problem - multidrug-resistant Clostridium difficile bacterial infection.

3 Aug 2011

Biotica acquires full rights to rapamycin analogue program from Pfizer

Biotica Technology Ltd. today announced that it has regained full rights from Pfizer Inc. to its rapamycin analogue program, including transfer of data and materials.

3 Aug 2011

VIB researchers develop mouse model for Charcot-Marie-Tooth neuropathy

VIB researchers have developed a mouse model for Charcot-Marie-Tooth (CMT) neuropathy, a hereditary disease of the peripheral nervous system.

3 Aug 2011

MSMB offers $18 per share for Amag acquisition

MSMB Capital Management today announced that it has made a proposal to the Board of Directors of Amag Pharmaceuticals Inc. to acquire all of the outstanding shares of common stock of Amag for $18 per share in cash or an aggregate of $378 million.

3 Aug 2011

SDIX adds nine new polyclonal antibodies to IVD reagents portfolio

SDIX, a leading provider of In Vitro Diagnostic (IVD) reagents, announced the addition of nine new polyclonal antibodies to its product line for the IVD market while exhibiting at AACC last week.

3 Aug 2011

Words+ introduces EyePro GS system

Words+, Inc., a leading provider of augmentative communication and assistive technology hardware and software for people with disabilities, announced today that it has launched EyePro GS™, a new product designed and manufactured in-house that allows a person to operate an augmentative communication system or computer by simply looking at the screen. Words+ is a wholly owned subsidiary of Simulations Plus, Inc..

2 Aug 2011

Simple ways to minimize health risks associated with cell phones

The dangers of cell phones have led to preventive policies in France, Israel, Finland, and India, and there are simple ways to minimize the health risks associated with exposure to the radiation energy they emit, according to Devra Lee Davis, PhD, MPH, President of the Environmental Health Trust, in a timely and informative interview featured in Alternative and Complementary Therapies, published by Mary Ann Liebert, Inc.

2 Aug 2011

BARDA awards contracts for development of drugs for radiation injury to the GI tract

The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

2 Aug 2011

Compugen second quarter net income increases to $1.2 million

Compugen Ltd. today reported its results for the second quarter ending June 30, 2011.

2 Aug 2011

Teva's ZOELY oral contraceptive receives EU Marketing Authorization

Teva Pharmaceutical Industries Ltd announced today that its new oral contraceptive, ZOELY, has received a Marketing Authorization in the European Union (EU) for the prevention of pregnancy.

2 Aug 2011

Elsevier launches new interactive feature for life sciences journals

Elsevier, a world-leading provider of scientific, technical and medical information products and services, introduces the Genome Viewer, a new interactive feature on SciVerse ScienceDirect for applicable life sciences journals.

2 Aug 2011

Can-Fite commences CF101 phase 2/3 trial for treatment of Psoriasis

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange announced today that it has commenced patient enrolment in a phase 2/3 clinical trial of CF101 for the treatment of Psoriasis.

2 Aug 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011